Removal of cytostatic drugs from aquatic environment: A review

Science of the Total Environment

Volumn 445-446, Issue , 2013, Pages 281-298

  Zhang, Jiefeng ^a   Chang, Victor W C ^a   Giannis, Apostolos ^b   Wang, Jing Yuan ^a,b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Cytostatic drugs; Ecotoxicity; Occurrence; Review; Treatment; Urine source separation

Indexed keywords

ADVANCED OXIDATION PROCESSES; AQUATIC ENVIRONMENTS; CHEMODYNAMICS; CONTROL STRATEGIES; CYTOSTATIC; ECOTOXICITY; ECOTOXICITY DATA; ECOTOXICOLOGICAL RISKS; ENVIRONMENTAL CONCENTRATION; HOSPITAL EFFLUENT; HUMAN METABOLITES; LITERATURE REVIEWS; MEMBRANE BIOREACTOR; NATURAL WATERS; OCCUPATIONAL EXPOSURE; OCCURRENCE; PHYSICO-CHEMICAL DATA; TRANSFORMATION PRODUCTS; TREATMENT; TREATMENT TECHNOLOGIES; URINARY EXCRETION; WATER CYCLE;

BODY FLUIDS; CHEMOTHERAPY; EFFLUENT TREATMENT; METADATA; REVIEWS;

SOURCE SEPARATION;

CYTOSTATIC AGENT; SURFACE WATER;

AQUATIC ENVIRONMENT; DRUG; ECOTOXICOLOGY; ENVIRONMENTAL FATE; METABOLITE; PHYSICOCHEMICAL PROPERTY; RISK ASSESSMENT; WATER TREATMENT;

ADSORPTION; AQUATIC ENVIRONMENT; BIOACCUMULATION; BIODEGRADATION; BIOREMEDIATION; CARCINOGENICITY; DRUG EXCRETION; ECOTOXICITY; EFFLUENT; ELECTRODIALYSIS; EVAPORATION; HOSPITAL WASTE; HUMAN; MEMBRANE FILTER; MUTAGENICITY; NONHUMAN; OXIDATION; OZONATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSE OSMOSIS; REVIEW; SEPARATION TECHNIQUE; SOLID WASTE MANAGEMENT; TERATOGENICITY; URINARY EXCRETION; WATER CYCLE;

CYTOSTATIC AGENTS; ECOSYSTEM; ENVIRONMENTAL EXPOSURE; FILTRATION; HUMANS; OXIDATION-REDUCTION; RISK ASSESSMENT; SPECTINOMYCIN; WATER POLLUTANTS, CHEMICAL; WATER PURIFICATION;

EID: 84872717833     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.12.061     Document Type: Review

References (153)

1. Achilli A., Cath T.Y., Marchand E.A., Childress A.E. The forward osmosis membrane bioreactor: a low fouling alternative to MBR processes. Desalination 2009, 238:10-21.
2. Alturki A.A., Tadkaew N., McDonald J.A., Khan S.J., Price W.E., Nghiem L.D. Combining MBR and NF/RO membrane filtration for the removal of trace organics in indirect potable water reuse applications. J Membr Sci 2010, 365:206-215.
3. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., et al. Screening analysis of human pharmaceutical compounds in US surface waters. Environ Sci Technol 2004, 38:838-849.
4. Andreozzi R., Raffaele M., Nicklas P. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:1319-1330.
5. Andrews W.J., Masoner J.R., Cozzarelli I.M. Emerging contaminants at a closed and an operating landfill in Oklahoma. Ground Water Monit Rem 2012, 32:120-130.
6. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333:167-184.
7. Avella A.C., Delgado L.F., Gorner T., Albasi C., Galmiche M., de Donato P. Effect of cytostatic drug presence on extracellular polymeric substances formation in municipal wastewater treated by membrane bioreactor. Bioresour Technol 2010, 101:518-526.
8. Beier S., Cramer C., Köster S., Mauer C., Palmowski L., Schröder H.F., et al. Full scale membrane bioreactor treatment of hospital wastewater as forerunner for hot-spot wastewater treatment solutions in high density urban areas. Water Sci Technol 2011, 63:66-71.
9. Ben Abdelmelek S., Greaves J., Ishida K.P., Cooper W.J., Song W.H. Removal of pharmaceutical and personal care products from reverse osmosis retentate using advanced oxidation processes. Environ Sci Technol 2011, 45:3665-3671.
10. Besse J.P., Kausch-Barreto C., Garric J. Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization. Hum Ecol Risk Assess 2008, 14:665-695.
11. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39:73-86.
12. Boillot C., Bazin C., Tissot-Guerraz F., Droguet J., Perraud M., Cetre J.C., et al. Daily physicochemical, microbiological and ecotoxicological fluctuations of a hospital effluent according to technical and care activities. Sci Total Environ 2008, 403:113-129.
13. Bolong N., Ismail A.F., Salim M.R., Matsuura T. A review of the effects of emerging contaminants in wastewater and options for their removal. Desalination 2009, 239:229-246.
14. Botton S., Verliefde A.R.D., Quach N.T., Cornelissen E.R. Influence of biofouling on pharmaceuticals rejection in NF membrane filtration. Water Res 2012, 46:5848-5860.
15. Bound J.P., Voulvoulis N. Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United Kingdom. Environ Health Perspect 2005, 113:1705-1711.
16. Bound J.P., Kitsou K., Voulvoulis N. Household disposal of pharmaceuticals and perception of risk to the environment. Environ Toxicol Pharmacol 2006, 21:301-307.
17. Bouraoui S., Brahem A., Tabka F., Mrizek N., Saad A., Elghezal H. Assessment of chromosomal aberrations, micronuclei and proliferation rate index in peripheral lymphocytes from Tunisian nurses handling cytotoxic drugs. Environ Toxicol Pharmacol 2011, 31:250-257.
18. Boxall A.B.A. The environmental side effects of medication-how are human and veterinary medicines in soils and water bodies affecting human and environmental health?. EMBO Rep 2004, 5:1110-1116.
19. Broseus R., Vincent S., Aboulfadl K., Daneshvar A., Sauve S., Barbeau B., et al. Ozone oxidation of pharmaceuticals, endocrine disruptors and pesticides during drinking water treatment. Water Res 2009, 43:4707-4717.
20. Buchberger W.W. Current approaches to trace analysis of pharmaceuticals and personal care products in the environment. J Chromatogr A 2011, 1218:603-618.
21. Buerge I.J., Buser H.R., Poiger T., Muller M.D. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 2006, 40:7242-7250.
22. Bumpas J., Betsch E. Exploratory study on active pharmaceutical ingredient manufacturing for essential medicines. Health, Nutrition and Population (HNP) Discussion Paper 2009, The World Bank.
23. Busetti F., Linge K.L., Heitz A. Analysis of pharmaceuticals in indirect potable reuse systems using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A 2009, 1216:5807-5818.
24. Calamari D., Zuccato E., Castiglioni S., Bagnati R., Fanelli R. Strategic survey of therapeutic drugs in the rivers Po and Lambro in Northern Italy. Environ Sci Technol 2003, 37:1241-1248.
25. Carlsson G., Orn S., Larsson D.G.J. Effluent from bulk drug production is toxic to aquatic vertebrates. Environ Toxicol Chem 2009, 28:2656-2662.
26. Chen C.Y., Lu C.L. An analysis of the combined effects of organic toxicants. Sci Total Environ 2002, 289:123-132.
27. Chen Z., Park G., Herckes P., Westerhoff P. Physicochemical treatment of three chemotherapy drugs: irinotecan, tamoxifen, and cyclophosphamide. J Adv Oxid Technol 2008, 11:254-260.
28. Coetsier C.M., Spinelli S., Lin L., Roig B., Touraud E. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ Int 2009, 35:787-792.
29. Conn K.E., Barber L.B., Brown G.K., Siegrist R.L. Occurrence and fate of organic contaminants during onsite wastewater treatment. Environ Sci Technol 2006, 40:7358-7366.
30. Crane M., Watts C., Boucard T. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ 2006, 367:23-41.
31. Daughton C.G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 2003, 111:757-774.
32. Daughton C.G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ Health Perspect 2003, 111:775-785.
33. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environ Health Perspect 1999, 107:907-938.
34. Delgado L.F., Dorandeu C., Marion B., Gonzalez C., Faucet-Marquis V., Schetrite S., et al. Removal of a cytostatic drug by a membrane bioreactor. Desalin Water Treat 2009, 9:112-118.
35. Delgado L.F., Faucet-Marquis V., Schetrite S., Pfohl-Leszkowicz A., Paranthoen S., Albasi C. Effect of cytostatic drugs on the sludge and on the mixed liquor characteristics of a cross-flow membrane bioreactor: consequence on the process. J Membr Sci 2010, 347:165-173.
36. Delgado L.F., Schetrite S., Gonzalez C., Albasi C. Effect of cytostatic drugs on microbial behaviour in membrane bioreactor system. Bioresour Technol 2010, 101:527-536.
37. Delgado L.F., Faucet-Marquis V., Pfohl-Leszkowicz A., Dorandeu C., Marion B., Schetrite S., et al. Cytotoxicity micropollutant removal in a crossflow membrane bioreactor. Bioresour Technol 2011, 102:4395-4401.
38. Delgado L.F., Charles P., Glucina K., Morlay C. QSAR-like models: a potential tool for the selection of PhACs and EDCs for monitoring purposes in drinking water treatment systems-a review. Water Res 2012, 46:6196-6209.
39. Dodd M.C., Zuleeg S., Von Gunten U., Pronk W. Ozonation of source-separated urine for resource recovery and waste minimization: process modeling, reaction chemistry, and operational considerations. Environ Sci Technol 2008, 42:9329-9337.
40. Doerr-MacEwen N.A., Haight M.E. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ Manage 2006, 38:853-866.
41. Doll T.E., Frimmel F.H. Fate of pharmaceuticals-photodegradation by simulated solar UV-light. Chemosphere 2003, 52:1757-1769.
42. Dorion E., Severo E., Olea P., Nodari C., De Guimaraes J.F. Hospital environmental and residues management: Brazilian experiences. J Environ Assess Manag 2012, 14.
43. EMEA Guideline on the environmental risk assessment of medicinal products for human use. CHMP/SWP/4447/00, London 2006, Agency EM (Ed.).
44. Emmanuel E., Perrodin Y., Keck G., Blanchard J.M., Vermande P. Ecotoxicological risk assessment of hospital wastewater: a proposed framework for raw effluents discharging into urban sewer network. J Hazard Mater 2005, 117:1-11.
45. EPA US EPA Method: 1694, Pharmaceuticals and personal care products in water, soil, sediment, and biosolids by HPLC/MS/MS. EPA-821-R-08-002 2007.
46. Escher B.I., Pronk W., Suter M.J.F., Maurer M. Monitoring the removal efficiency of pharmaceuticals and hormones in different treatment processes of source-separated urine with bioassays. Environ Sci Technol 2006, 40:5095-5101.
47. Escher B.I., Baumgartner R., Koller M., Treyer K., Lienert J., McArdell C.S. Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res 2011, 45:75-92.
48. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76:122-159.
49. Ferk F., Misik M., Grummt T., Majer B., Fuerhacker M., Buchmann C., et al. Genotoxic effects of wastewater from an oncological ward. Mutat Res Genet Toxicol Environ Mutagen 2009, 672:69-75.
50. Fick J., Soderstrom H., Lindberg R.H., Phan C., Tysklind M., Larsson D.G.J. Contamination of surface, ground, and drinking water from pharmaceutical production. Environ Toxicol Chem 2009, 28:2522-2527.
51. Fitzke B., Geissen S.U. Sustainable removal of iodinated X-ray contrast media (XRC) by ozonation in a complex wastewater matrix-urine as example. Water Sci Technol 2007, 55:293-300.
52. Franke C., Studinger G., Berger G., Bohling S., Bruckmann U., Cohorsfresenborg D., et al. The assessment of bioaccumulation. Chemosphere 1994, 29:1501-1514.
53. Garcia-Ac A., Broseus R., Vincent S., Barbeau B., Prevost M., Sauve S. Oxidation kinetics of cyclophosphamide and methotrexate by ozone in drinking water. Chemosphere 2010, 79:1056-1063.
54. Ghauch A., Tuqan A., Assi H.A. Antibiotic removal from water: elimination of amoxicillin and ampicillin by microscale and nanoscale iron particles. Environ Pollut 2009, 157:1626-1635.
55. Glassmeyer S.T., Furlong E.T., Kolpin D.W., Cahill J.D., Zaugg S.D., Werner S.L., et al. Transport of chemical and microbial compounds from known wastewater discharges: potential for use as indicators of human fecal contamination. Environ Sci Technol 2005, 39:5157-5169.
56. Gómez-Canela C., Cortés-Francisco N., Oliva X., Pujol C., Ventura F., Lacorte S., et al. Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry. Environ Sci Pollut Res 2012, 19:3210-3218.
57. Gunnarsson L., Kristiansson E., Rutgersson C., Sturve J., Fick J., Forlin L., et al. Pharmaceutical industry effluent diluted 1:500 affects global gene expression, cytochrome P450 1a activity, and plasma phosphate in fish. Environ Toxicol Chem 2009, 28:2639-2647.
58. Hansen P.D. Risk assessment of emerging contaminants in aquatic systems. TrAC Trends Anal Chem 2007, 26:1095-1099.
59. Hellström D., Johansson E. Swedish experiences with urine separating systems. Wasser Boden 1999, 51:26-29.
60. Hernando M.D., Mezcua M., Fernandez-Alba A.R., Barcelo D. Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 2006, 69:334-342.
61. Hirose J., Kondo F., Nakano T., Kobayashi T., Hiro N., Ando Y., et al. Inactivation of antineoplastics in clinical wastewater by electrolysis. Chemosphere 2005, 60:1018-1024.
62. Holloway R.W., Childress A.E., Dennett K.E., Cath T.Y. Forward osmosis for concentration of anaerobic digester centrate. Water Res 2007, 41:4005-4014.
63. Ieropoulos I., Greenman J., Melhuish C. Urine utilisation by microbial fuel cells; energy fuel for the future. Phys Chem Chem Phys 2012, 14:94-98.
64. IMAP Pharmaceuticals and Biotech Industry Global Report-2011. An IMAP Healthcare Report 2011.
65. Jin X., Shan J., Wang C., Wei J., Tang C.Y. Rejection of pharmaceuticals by forward osmosis membranes. J Hazard Mater 2012, 227-228:55-61.
66. Johnson A.C., Jurgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348:167-175.
67. Jones O.A.H., Green P.G., Voulvoulis N., Lester J.N. Questioning the excessive use of advanced treatment to remove organic micropollutants from wastewater. Environ Sci Technol 2007, 41:5085-5089.
68. Judson I.R., Beale P.J., Trigo J.M., Aherne W., Crompton T., Jones D., et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of C-14-labelled drug. Invest New Drugs 1999, 17:49-56.
69. Khetan S.K., Collins T.J. Human pharmaceuticals in the aquatic environment: a challenge to green chemistry. Chem Rev 2007, 107:2319-2364.
70. Kiffmeyer T., Gotze H.J., Jursch M., Luders U. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius J Anal Chem 1998, 361:185-191.
71. 2 2008, 57:195-200.
72. 2 treatments. Chemosphere 2009, 77:518-525.
73. Kimura K., Amy G., Drewes J.E., Heberer T., Kim T.U., Watanabe Y. Rejection of organic micropollutants (disinfection by-products, endocrine disrupting compounds, and pharmaceutically active compounds) by NF/RO membranes. J Membr Sci 2003, 227:113-121.
74. Kobayashi T., Hirose J., Sano K., Kato R., Ijiri Y., Takiuchi H., et al. Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicol Environ Saf 2012, 78:123-127.
75. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 36:1202-1211.
76. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. TrAC Trends Anal Chem 2011, 30:1065-1087.
77. Kovalova L., McArdell C.S., Hollender J. Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. J Chromatogr A 2009, 1216:1100-1108.
78. Kovalova L., Siegrist H., Singer H., Wittmer A., McArdell C.S. Hospital wastewater treatment by membrane bioreactor: performance and efficiency for organic micropollutant elimination. Environ Sci Technol 2012, 46:1536-1545.
79. Kümmerer K. Pharmaceuticals in the environment. Annu Rev Environ Resour 2010, 35:57-75.
80. Kümmerer K., Al-Ahmad A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res 2010, 17:486-496.
81. Kümmerer K., StegerHartmann T., Meyer M. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res 1997, 31:2705-2710.
82. Laenge R., Steger-Hartmann T., Schweinfurth H. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process. Regul Toxicol Pharmacol 2006, 45:223-228.
83. Larsen T.A., Gujer W. Separate management of anthropogenic nutrient solutions (human urine). Water Sci Technol 1996, 34:87-94.
84. Larsen T.A., Lienert J., Joss A., Siegrist H. How to avoid pharmaceuticals in the aquatic environment. J Biotechnol 2004, 113:295-304.
85. Larsen T.A., Alder A.C., Eggen R.I.L., Maurer M., Lienert J. Source separation: will we see a paradigm shift in wastewater handling?. Environ Sci Technol 2009, 43:6121-6125.
86. Larsson D.G.J. Drug production facilities-an overlooked discharge source for pharmaceuticals to the environment. Pharmaceuticals in the environment: sources, fate, effects and risks 2008, Springer Verlag, Berlin Heidelberg. K. Kümmerer (Ed.).
87. Larsson D.G.J., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 2007, 148:751-755.
88. Lazarova Z., Spendlingwimmer R. Treatment of yellow water by membrane separations and advanced oxidation methods. Water Sci Technol 2008, 58:419-426.
89. Lenz K., Koellensperger G., Hann S., Weissenbacher N., Mahnik S.N., Fuerhacker M. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 2007, 69:1765-1774.
90. Lenz K., Mahnik S.N., Weissenbacher N., Mader R.M., Krenn P., Hann S., et al. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci Technol 2007, 56:141-149.
91. Lester Y., Avisar D., Gozlan I., Mamane H. Removal of pharmaceuticals using combination of UV/H 2O 2/O 3 advanced oxidation process. Water Sci Technol 2011, 64:2230-2238.
92. Li X.Q., Hai F.I., Nghiem L.D. Simultaneous activated carbon adsorption within a membrane bioreactor for an enhanced micropollutant removal. Bioresour Technol 2011, 102:5319-5324.
93. Lienert J., Larsen T.A. High acceptance of urine source separation in seven European countries: a review. Environ Sci Technol 2010, 44:556-566.
94. Lienert J., Burki T., Escher B.I. Reducing micropollutants with source control: substance flow analysis of 212 pharmaceuticals in faeces and urine. Water Sci Technol 2007, 56:87-96.
95. Lienert J., Koller M., Konrad J., McArdell C.S., Schuwirth N. Multiple-criteria decision analysis reveals high stakeholder preference to remove pharmaceuticals from hospital wastewater. Environ Sci Technol 2011, 45:3848-3857.
96. Llewellyn N., Lloyd P., Jürgens M.D., Johnson A.C. Determination of cyclophosphamide and ifosfamide in sewage effluent by stable isotope-dilution liquid chromatography-tandem mass spectrometry. J Chromatogr A 2011, 1218:8519-8528.
97. Low G.K.C., McEvoy S.R., Matthews R.W. Formation of nitrate and ammonium ions in titanium dioxide mediated photocatalytic degradation of organic compounds containing nitrogen atoms. Environ Sci Technol 1991, 25:460-467.
98. Mahnik S.N., Rizovski B., Fuerhacker M., Mader R.M. Determination of 5-fluorouracil in hospital effluents. Anal Bioanal Chem 2004, 380:31-35.
99. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66:30-37.
100. Martin Ruel S., Choubert J.M., Esperanza M., Miège C., Navalón Madrigal P., Budzinski H., et al. On-site evaluation of the removal of 100 micro-pollutants through advanced wastewater treatment processes for reuse applications. Water Sci Technol 2011, 63:2486-2497.
101. Martin J., Camacho-Munoz D., Santos J.L., Aparicio I., Alonso E. Simultaneous determination of a selected group of cytostatic drugs in water using high-performance liquid chromatography-triple-quadrupole mass spectrometry. J Sep Sci 2011, 34:3166-3177.
102. Maurer M., Pronk W., Larsen T.A. Treatment processes for source-separated urine. Water Res 2006, 40:3151-3166.
103. Meinzinger F., Oldenburg M. Characteristics of source-separated household wastewater flows: a statistical assessment. Water Sci Technol 2009, 59:1785-1791.
104. Moldovan Z. Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania. Chemosphere 2006, 64:1808-1817.
105. Mompelat S., Le Bot B., Thomas O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ Int 2009, 35:803-814.
106. Musson S.E., Townsend T.G. Pharmaceutical compound content of municipal solid waste. J Hazard Mater 2009, 162:730-735.
107. Nakano E., Watanabe L.C., Ohlweiler F.P., Pereira C.A.D., Kawano T. Establishment of the dominant lethal test in the freshwater mollusk Biomphalaria glabrata (Say, 1818). Mutat Res Genet Toxicol Environ Mutagen 2003, 536:145-154.
108. Nghiem L.D., Schafer A.I., Elimelech M. Pharmaceutical retention mechanisms by nanofiltration membranes. Environ Sci Technol 2005, 39:7698-7705.
109. Nussbaumer S., Fleury-Souverain S., Antinori P., Sadeghipour F., Hochstrasser D.F., Bonnabry P., et al. Simultaneous quantification of ten cytotoxic drugs by a validated LC-ESI-MS/MS method. Anal Bioanal Chem 2010, 398:3033-3042.
110. Ort C., Lawrence M.G., Reungoat J., Eaglesham G., Carter S., Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res 2010, 44:605-615.
111. Pérez G., Fernández-Alba A.R., Urtiaga A.M., Ortiz I. Electro-oxidation of reverse osmosis concentrates generated in tertiary water treatment. Water Res 2010, 44:2763-2772.
112. Pomati F., Castiglioni S., Zuccato E., Fanelli R., Vigetti D., Rossetti C., et al. Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. Environ Sci Technol 2006, 40:2442-2447.
113. Pronk W., Kone D. Options for urine treatment in developing countries. Desalination 2009, 248:360-368.
114. Pronk W., Biebow M., Boller M. Electrodialysis for recovering salts from a urine solution containing micropollutants. Environ Sci Technol 2006, 40:2414-2420.
115. Pronk W., Palmquist H., Biebow M., Boller M. Nanofiltration for the separation of pharmaceuticals from nutrients in source-separated urine. Water Res 2006, 40:1405-1412.
116. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
117. Ronteltap M., Maurer M., Gujer W. The behaviour of pharmaceuticals and heavy metals during struvite precipitation in urine. Water Res 2007, 41:1859-1868.
118. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009, 28:2733-2743.
119. Sasu S., Metzger J., Kranert M., Kümmerer K. A glance at the world: investigating pharmaceutical waste management in Ghana. Waste Manag 2011, 31:2361-2363.
120. Sasu S., Kümmerer K., Kranert M. Assessment of pharmaceutical waste management at selected hospitals and homes in Ghana. Waste Manag Res 2012, 30:625-630.
121. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess 2002, 8:657-680.
122. Sessink P.J.M., White R.E., Easty A.C., Mahmoud S., Leonard D., Jacklin A., et al. Safety considerations in oncology pharmacy 2011, Pharma Publishing & Media Europe, Belgium.
123. Smerhovsky Z., Landa K., Rossner P., Brabec M., Zudova Z., Hola N., et al. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect 2001, 109:41-45.
124. Smith G.A., Zaffiro A.D., Zimmerman M.L., Munch D.J. Method 539: determination of hormones in drinking water by solid phase extraction (SPE) and liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS). EPA Document No. 815-B-10-001 2010, EPA U (Ed.).
125. Snyder S.A., Adham S., Redding A.M., Cannon F.S., DeCarolis J., Oppenheimer J., et al. Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals. Desalination 2007, 202:156-181.
126. Somensi C.A., Simionatto E.L., Dalmarco J.B., Gaspareto P., Radetski C.M. A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: kinetic and efficiency approaches. J Environ Sci Health A Tox Hazard Subst Environ Eng 2012, 47:1543-1550.
127. StegerHartmann T., Kümmerer K., Hartmann A. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol Environ Saf 1997, 36:174-179.
128. Steger-Hartmann T., Kümmerer K., Schecker J. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by two-step solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr A 1996, 726:179-184.
129. Stieber M., Putschew A., Jekel M. Treatment of pharmaceuticals and diagnostic agents using zero-valent iron-kinetic studies and assessment of transformation products assay. Environ Sci Technol 2011, 45:4944-4950.
130. Straub J.O. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe. Integr Environ Assess Manag 2010, 6(Supplement 1):540-566.
131. Tauxe-Wuersch A., de Alencastro L.F., Grandjean D., Tarradellas J. Trace determination of tamoxifen and 5-fluorouracil in hospital and urban wastewaters. Int J Environ Anal Chem 2006, 86:473-485.
132. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 32:3245-3260.
133. Thomas K.V., Dye C., Schlabach M., Langford K.H. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 2007, 9:1410-1418.
134. Tuerk J., Kiffmeyer T.K., Hadtstein C., Heinemann A., Hahn M., Stuetzer H., et al. Development and validation of an LC-MS/MS procedure for environmental monitoring of eight cytostatic drugs in pharmacies. Int J Environ Anal Chem 2011, 91:1178-1190.
135. Turci R., Sottani C., Spagnoli G., Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B 2003, 789:169-209.
136. Udert K.M., Larsen T.A., Gujer W. Fate of major compounds in source-separated urine. Water Sci Technol 2006, 54:413-420.
137. Valcarcel Y., Alonso S.G., Rodriguez-Gil J.L., Gil A., Catala M. Detection of pharmaceutically active compounds in the rivers and tap water of the Madrid Region (Spain) and potential ecotoxicological risk. Chemosphere 2011, 84:1336-1348.
138. Verlicchi P., Galletti A., Petrovic M., Barcelo D. Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options. J Hydrol 2010, 389:416-428.
139. Verlicchi P., Al Aukidy M., Galletti A., Petrovic M., Barceló D. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci Total Environ 2012, 430:109-118.
140. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment-a review. Sci Total Environ 2012, 429:123-155.
141. Verliefde A.R.D., Heijman S.G.J., Cornelissen E.R., Amy G., Van der Bruggen B., van Dijk J.C. Influence of electrostatic interactions on the rejection with NF and assessment of the removal efficiency during NF/GAC treatment of pharmaceutically active compounds in surface water. Water Res 2007, 41:3227-3240.
142. von Gunten U. Ozonation of drinking water: Part I. Oxidation kinetics and product formation. Water Res 2003, 37:1443-1467.
143. Wang L., Albasi C., Faucet-Marquis V., Pfohl-Leszkowicz A., Dorandeu C., Marion B., et al. Cyclophosphamide removal from water by nanofiltration and reverse osmosis membrane. Water Res 2009, 43:4115-4122.
144. Weissbrodt D., Kovalova L., Ort C., Pazhepurackel V., Moser R., Hollender J., et al. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environ Sci Technol 2009, 43:4810-4817.
145. Westerhoff P., Yoon Y., Snyder S., Wert E. Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes. Environ Sci Technol 2005, 39:6649-6663.
146. WHO World Cancer Report 2008. 150 cours Albert Thomas, 69372 Lyon Cedex 08, France 2008, P. Boyle, B. Levin (Eds.).
147. Wilsenach J.A., Van Loosdrecht M.C.M. Effects of separate urine collection on advanced nutrient removal processes. Environ Sci Technol 2004, 38:1208-1215.
148. Winker M., Faika D., Gulyas H., Otterpohl R. A comparison of human pharmaceutical concentrations in raw municipal wastewater and yellowwater. Sci Total Environ 2008, 399:96-104.
149. Xie M., Price W.E., Nghiem L.D. Rejection of pharmaceutically active compounds by forward osmosis: role of solution pH and membrane orientation. Sep Purif Technol 2012, 93:107-114.
150. Yin J., Shao B., Zhang J., Li K.J. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull Environ Contam Toxicol 2010, 84:39-45.
151. Zhang JF, Giannis A, Ng JHB, Chang W-CV, Wang JY. Adaptation of urine source separation in tropical cities: process optimization and odor mitigation. J Air Waste Manag Assoc in press.
152. Zhao S.F., Zou L., Tang C.Y.Y., Mulcahy D. Recent developments in forward osmosis: opportunities and challenges. J Membr Sci 2012, 396:1-21.
153. Zuccato E., Castiglioni S., Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J Hazard Mater 2005, 122:205-209.